

Wholesale Acquisition Cost Information for Colorado Prescribers

GOMEKLI® (mirdametinib)

Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below.

NDC	Product	Dosage Form	Strength	Unit Size	Wholesale Acquisition Cost*
82448-0130-42	GOMEKLI®	Capsule	1mg	42	\$9,355.50
82448-0260-42	GOMEKLI®	Capsule	2mg	42	\$18,711.00
82448-0260-84	GOMEKLI®	Capsule	2mg	84	\$37,422.00
82448-0134-42	GOMEKLI®	Tablet Soluble	1mg	42	\$9,355.50
82448-0134-84	GOMEKLI®	Tablet Soluble	1mg	84	\$18,711.00

The price paid by patients to acquire the product listed is often different than the WAC price listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy.

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” Generic versions of GOMEKLI are not currently available.

*The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.

GOMEKLI® is a registered trademark of SpringWorks Therapeutics, a healthcare company of Merck KGaA Darmstadt, Germany
©2026 SpringWorks Therapeutics, all rights reserved.
01/05/2026

© February 2025 SpringWorks Therapeutics, Inc.